Methotrexate induced pneumonitis is a rare (0.3-7.5%) (1-3) but serious and potentially fatal complication (4) of the treatment with this folic acid antagonist in patients with rheumatoid arthritis (RA) and other diseases. Typically, it begins as an acute or subacute episode of dry cough, dyspnea and fever, within the first year of treatment, more frequently during the first months (mean: 36-78 weeks) (5), and, regardless of the prescribed dose, smoking habits and gender of the patient. Other risk factors such as advanced age, extra-articular manifestations of rheumatoid arthritis (especially pulmonary involvement), diabetes and elevated creatinine level, have been identified (6). If suspected, methotrexate should be discontinued immediately and respiratory support treatment plus systemic steroids at medium-high doses should be initiated. In addition, it is recommended to associate a broad spectrum antibiotic treatment, covering Pneumocystis jirovecii (7), until the infectious origin is discarded (2). We present a 71-year-old female who presented this rare pathology three years ago, as a consequence of being treated with methotrexate (MTX) for rheumatoid arthritis diagnosed three months earlier.
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CASE PRESENTATION:
In June 2013, a non-smoker 68-yearold woman, suffering from diabetes and seronegative-RA who had been on methotrexate plus folic acid supplementation for three months, was admitted in the Intensive Care Unit of our hospital. During the previous 24 hours, she had presented dyspnea, cough, sweating, nausea, fever and dizziness. She had low pressure and oxygen levels, and so was initially treated with a basic support therapy and empiric antibiotic, imipenem. She had no fever, but her neutrophil count was high (78%), without eosinophilia and a normal total leukocyte count. The initial chest X-ray study showed diffuse interstitial infiltrates in the lower airways (figure 1).
FIGURE 1. Chest X-ray on admission
Acute pulmonary edema and infection were discarded, since procalcitonin levels never raised and cultures of sputum, blood and urine were negative. Quantiferon test was negative. Taking into account her medical history, methotrexate induced pneumonitis was suspected and therefore 80 mg intravenous methylprednisolone was added daily to her treatment, and also methotrexate was immediately discontinued. Within two days, she improved and was moved to the hospitalization area. Pulmonary CT was performed (figure 2A), confirming the presence of an extensive bilateral ground-glass pattern of peripheral predominance, associated with minimal subpleural condensations in the lower right lobe. The preserved lung parenchyma was normal. Bronchoalveolar lavage fluid (BALF) was not done, and lung biopsy was not practiced. Echocardiographic findings showed a normal cardiac function. Pulmonary function tests were taken, but due to a lack of collaboration from the patient, results were not valid. The patient was discharged in one week with oral steroid treatment (0.5 mg/kg/day) for external follow-up. Sulphasalazine was added to her treatment, and abandoned within a few weeks due to hair loss, abdominal pain and palpable purple in her abdomen and root of her four limbs. Therefore, she continued treatment with oral prednisone alone, tapering the dose up to 7.5 mg/day. In a few weeks, the patient was fully recovered. After 10 months, a high resolution computerized axial tomography scan was performed (figure 2B), a normal pulmonary parenchyma was observed, with disappearance of the pattern in ground glass. She completely recovered her daily activities. We tried twice to taper the steroids dose, but arthritis relapsed.
However, when arthritis had been controlled for several months with oral prednisone (7.5 mg/day), she was referred to the Hematologist because of a chronic anemia that she had been presenting prior to the arthritis. After a bone marrow biopsy, she was diagnosed of low grade myelodysplastic syndrome, not needing further treatment, except for some iron supplements from time to time.
The patient suffered a hip fracture on October 2013, leading treatment into a more complicated issue. Her bone densitometry showed lumbar T-score -2.1 SD and total hip T-score -0.8 SD. The patient rejected Osteoporosis drug-treatment; albeit she agreed on taking a rich calcium diet and some exercise.
Currently, the patient maintains low disease activity and has a normal lifestyle. Her respiratory function remains normal. No infectious complications have been noticed. No more bone fractures have been reported.
DISCUSSION:
Immunosuppressants and immunomodulators such as methotrexate are used to adjust excessive immune response in rheumatic diseases. Unfortunately, these drugs have a potential broad toxicity spectrum, from gastric discomfort to a solid organ injury, leading into cytopenias or hair loss, among others. In 2014, Roubille and Haraoui (8) performed a systematic literature review for cases related with lung toxicity in RA patients treated either with classic DMARDs, biologic DMARDs or both. This revision concluded that any of these drugs (except anakinra or hydroxychloroquine) could cause lung injury as a side effect, or even worsen a previous interstitial lung disease in a RA patient.
Regarding methotrexate therapy, induced lung toxicity has currently been described as an acute interstitial pneumonitis (hypersensitivity pulmonary reaction), interstitial fibrosis, bronchiolitis obliterans with organized pneumonia (BOOP) pleural effusion, pulmonary nodules, noncardiogenic pulmonary edema, and bronchitis with airway hyperreactivity; more rarely as a chronic pneumonitis, although this last circumstance is still under discussion. Acute interstitial pneumonitis is the most common, followed by interstitial fibrosis, with all other conditions being very rare.
All of these complications have been reported in patients with RA under low dose MTX (9), although its initial mechanism remains still unclear since published data mainly come from case reports and not from large series studies, hence no complete details from pulmonary function tests, cultures or biopsy are available, and it is important to note that real patients usually combine different pharmaceutical products which may trigger or magnify methotrexate potential by injuring the lungs. However, the most likely hypothesis explaining the methotrexate induced pneumonitis stands that an idiosyncratic hypersensitivity reaction (stimulation of type 2 alveolar cells by activated CD4 and CD8T-cell) would lead to recruitment of inflammatory cells in the lungs, leading to alveolitis (10).
Furthermore, one should not forget that the initial differential diagnosis includes cardiac failure and primarily lung infection (1); this way, high spectrum antibiotic is mandatory until colonization is discarded. In addition, high dose steroids and respiratory support are to be used promptly in order to stabilize the patient and reduce lung inflammation, and both can be tapered as soon as the patient starts improving, even though oral steroids should be maintained for a few weeks. Full methotrexate interruption is obviously necessary. Finally, we ought to take into account that this situation is very serious and has a potentially fatal outcome if not treated properly in time.
Fortunately, in our patient, pneumonitis induced by methotrexate was foreseen and treated, successfully. After three years, our patient has an absolute normal life; her arthritis remains in lowactivity, only receiving a low-dose steroids treatment. During this follow-up, no other drawbacks have been registered, except for a hip fracture. After a comprehensive bibliographic search, we have not found other literature references that describe the long-term follow-up evolution in patients diagnosed with methotrexate-induced pneumonitis.
CONCLUSIONS:
Methotrexate-induced pneumonitis is a rare but potentially lethal complication of this folic-acid antagonist. It must be suspected in a patient treated with methotrexate presenting with acute dyspnea, dry cough, fever and general malaise accompanied by cyanosis and hypoxemia. Treatment with respiratory support and steroids is mandatory, as well as antibiotic prevention until infection is discarded. Methotrexate should be permanently discontinued. If treated promptly, response
